SIAPS’ role to control malaria was recently featured in Health & Humanitarian: The Supply Chain Review. Between 2000 and 2015, malaria case incidences declined by 41% and mortality rates by 62%. However, approximately 212 million people were infected and 429,000 people died in 2015, with the majority being children under the age of 5 in […]
Archive | Democratic Republic of CongoRSS feed for this section
SIAPS has received funding from the US President’s Malaria Initiative (PMI) to work in eight countries—Angola, Burundi, Democratic Republic of the Congo (DRC), Ethiopia, Kenya, Guinea, Mali, and South Sudan—to strengthen pharmaceutical systems for improved malaria control. This report synthesizes the pharmaceutical systems strengthening efforts of SIAPS and documents how the approach was used to support efforts to control malaria.
Defeating malaria through pharmaceutical systems strengthening: A review of SIAPS’s activities in eight countries
SIAPS recently published the results of its activities in eight countries (Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Kenya, Guinea, Mali, and South Sudan) to control malaria. This report summarizes systems strengthening interventions that support the prevention and treatment of malaria. With funding from the US President’s Malaria Initiative (PMI) and based […]
Implementing QuanTB to Improve Forecasting, Supply Planning, and Early Warning Systems for TB Medicines: Democratic Republic of the Congo Report
The goal of this project was to conduct a review of SIAPS TB technical assistance and QuanTB implementation in DRC. Specific objectives were to determine:
- Key achievements or results of SIAPS QuanTB technical assistance in DRC
- Experiences and perspectives of the beneficiaries from the NTP
- Challenges and lessons learned
This report summarizes key aspects and results of the review.
Technical Highlight: Strengthening Regulatory Systems in Democratic Republic of the Congo to Improve Access to Safe, Effective, and Quality Medicines
Chronic underfunding of the health sector coupled with long-term civil unrest in the Democratic Republic of the Congo (DRC) has contributed to insufficient regulatory capacity to effectively manage the registration and approval of new medicines in the country. In partnership with the USAID-funded SIAPS Program, the country’s Ministry of Health supported a number of broad interventions to strengthen DRC’s pharmaceutical regulatory system. SIAPS provides technical assistance to the three national control programs—malaria, HIV/AIDS, and tuberculosis—to improving access to quality medicines and other commodities and increase the potential for achieving desired health outcomes.
Addressing the Challenge of Supply Coordination in DRC: SIAPS and the National Malaria Control Program in Haut-Katanga
By Dr. Jonathan Luc Matala, Moise Kazadi, and Pacifique Bwenge Supply chain management includes coordinating and collaborating with partners at all levels, who serve as links to the end users, to ensure that commodities are available when and where they are needed, thereby avoiding wastage and expiry. To strengthen DRC’s interventions and coordinate its supporting […]
DRC Launching Pilot Standard Therapeutic Guidelines for Hospitals and Improving Patient Care with Drug Therapeutic Committees
By Dr. Jonathan Luc Matala and Julie Mbo In 2012, DRC decided to reinforce drug therapeutic committees (DTCs) in nine hospitals that were previously installed by the Strengthening Pharmaceutical Systems (SPS) Program. DRC asked the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program, which is funded by the US Agency for International Development […]
SIAPS technical support has helped strengthen the capacity of the national registration committee and streamline medicines registration. As a result, the number of registered medicines has increased from 200 in 2010 to over 3,000 in 2014; 72% of the medicines included on DRC’s essential medicines list currently have at least one product registered, up from 44% in 2011. The backlog of applications has been completely eliminated and the time taken to process a new application has been reduced from a peak of 85 days in 2013 to 64 days at the end of 2014.
Systems for Improved Access to Pharmaceuticals and Services: Malaria Quarterly Update – January—March 2016
Working closely with the President’s Malaria Initiative (PMI) in both Washington and PMI- focus countries, the US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program aims to ensure the availability of quality pharmaceutical products and effective pharmaceutical services in support of PMI objectives. To this end, and based on the PMI’s priorities, SIAPS endeavors to improve pharmaceutical governance, build capacity to manage malaria products while addressing the information needed for managing them, strengthen financing strategies and mechanisms to improve access to malaria medicines, and improve the quality of pharmaceutical services provided to malaria patients.
The SIAPS technical approach emphasizes health systems strengthening with a special focus on improving metrics, monitoring and evaluation (M&E), developing the capacity of local governments and organizations, and increasing country ownership. Through this approach, SIAPS aims to promote the availability and use of malaria products, including artemisinin-based combination therapy (ACT), rapid diagnostic tests (RDT), and medicines for severe malaria. At the country level, SIAPS collaborates with national malaria control programs and Central Medical Stores (CMS) to develop and implement strategies to strengthen pharmaceutical management to prevent and improve case management of malaria. Areas supported by SIAPS include: training; quantification; strengthening supply chain systems, including logistics management information; community and malaria case management; rational use; and medication safety. SIAPS works to strengthen malaria pharmaceutical management at the national level in Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Guinea, Mali, Niger, and South Sudan. In addition, SIAPS provides regional support in Latin America.
This report describes the major activities that SIAPS conducted at the global level and in each of the countries and region mentioned above between January and March 2016.
Analysis of Bottlenecks Related to Demand, Supply, and Use of Antibiotics for the Treatment of Neonatal Sepsis in the DRC
This study was initiated by the Direction de la Santé de la Famille et de Groupes Spécifiques (D10) and the Ministry of Public Health and carried out with technical and financial assistance from the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) and Integrated Health Project (PROSANI-Plus) implemented by Management Sciences for Health (MSH). The study stems from the many efforts by the Government and its partners to reduce maternal, infant, and, specifically, neonatal mortality.
Funding for the study, the report, and its dissemination was obtained from the Global Technical Reference Team for injectable antibiotics through the convener of the group, Save the Children.
- Pharmaceutical management considerations for expanded coverage of essential health services and financial protection programs
The UN adoption of the SDGs in 2015 signaled a strong commitment of member countries to the expanded access to […]
SIAPS provided technical assistance to facilitate the expedited assessment and registration of new and existing ARV formulations to support the […]
- Strengthening Registration and Quality Assurance Systems for Generic ARVs, Related Medicines, and Devices in Namibia
In Namibia, USAID has been providing funding for technical assistance in the areas of pharmaceutical management and systems strengthening since […]